SCHEDULE 13G

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

SCHEDULE 13G

 

Information to be Included in Statements Filed

Pursuant to Rules 13d-1(b), (c) and (d) and Amendments

Thereto Filed Pursuant to Rule 13d-2(b)

 

Under the Securities Exchange Act of 1934

 

 

IMMUNOMEDICS, INC.


(Name of Issuer)

 

Common Stock, $0.01 Par Value


(Title of Class of Securities)

 

452907 10 8


(CUSIP Number)

 

September 1, 2003


(Date of Event Which Requires Filing of this Statement)

 

 

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

 

¨ Rule 13d-1(b)

 

x Rule 13d-1(c)

 

¨ Rule 13d-1(d)

 

*The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

 

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

 

Page 1 of 6 pages


CUSIP NO.     452907 10 8                                             13G                                                 Page 2 of 6 Pages

 


  1.  

NAMES OF REPORTING PERSONS

I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)

 

             Deborah S. Orlove

   

  2.  

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

(a)  ¨

(b)  ¨

   

  3.  

SEC USE ONLY

 

   

  4.  

CITIZENSHIP OR PLACE OF ORGANIZATION

 

             United States

   

NUMBER OF

SHARES

BENEFICIALLY

OWNED BY

EACH

REPORTING

PERSON

WITH

 

  5.    SOLE VOTING POWER

 

1,015,017                


  6.    SHARED VOTING POWER

 

2,005,433                


  7.    SOLE DISPOSITIVE POWER

 

1,015,017                


  8.    SHARED DISPOSITIVE POWER

 

2,005,433                


  9.  

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

            3,020,450

   

10.  

CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*

 

¨

   

11.  

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

 

            6.06%

   

12.  

TYPE OF REPORTING PERSON*

 

            IN

   

 

*SEE INSTRUCTIONS BEFORE FILLING OUT!

 

 

Page 2 of 6 pages


Item 1(a).

Name of Issuer:

 

Immunomedics, Inc.

 

Item 1(b).

Address of Issuer’s Principal Executive Offices:

 

300 American Road

Morris Plains, New Jersey 07950

 

Item 2(a).

Name of Person Filing:

 

(i)    Deborah S. Orlove

 

Item 2(b).

Address of Principal Business Office or, if None, Residence:

 

(i)    2000 L St. NW, Suite 675, Washington, D.C. 20036

 

Item 2(c).

Citizenship:

 

(i)    United States

 

Item 2(d).

Title of Class of Securities:

 

Common Stock, $0.01 par value

 

Item 2(e).

CUSIP Number:

 

452907 10 8

 

Item 3.

If This Statement is Filed Pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person Filing is a:

 

(a)    ¨    Broker or dealer registered under Section 15 of the Exchange Act.

 

(b)    ¨    Bank as defined in Section 3(a)(6) of the Exchange Act.

 

(c)    ¨    Insurance company as defined in Section 3(a)(19) of the Exchange Act.

 

(d)    ¨    Investment company registered under Section 8 of the Investment Company Act.

 

(e)    ¨    An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E).

 

Page 3 of 6 pages


(f)    ¨    An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F).

 

(g)    ¨    A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G).

 

(h)    ¨    A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act.

 

(i)    ¨    A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act.

 

(j)    ¨    Group, in accordance with Rule 13d-1(b)(1)(ii)(J).

 

If this statement is filed pursuant to Rule 13d-1(c), check this box.     x

 

Item 4.

Ownership

 

Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

 

(i)

Deborah S. Orlove

 

(a)    Amount beneficially owned: 3,020,450

 

(b)    Percent of class: 6.06%

 

(c)    Number of shares as to which such person has:

 

(i)    sole power to vote or to direct the vote:     1,015,017

 

(ii)    shared power to vote or to direct the vote:     2,005,433

 

(iii)    sole power to dispose or to direct the disposition of:     1,015,017

 

(iv)    shared power to dispose or to direct the disposition of:     2,005,433

 

Item 5.

Ownership of Five Percent or Less of a Class

 

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following     ¨.

 

Page 4 of 6 pages


Item 6.

Ownership of More than Five Percent on Behalf of Another Person

 

Not Applicable.

 

Item 7.

Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company

 

Not Applicable.

 

Item 8.

Identification and Classification of Members of the Group

 

Not Applicable.

 

Item 9.

Notice of Dissolution of Group

 

Not Applicable.

 

Item 10.

Certification

 

By signing below each of the undersigned certifies that, to the best of her knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

 

Page 5 of 6 pages


SIGNATURE

 

After reasonable inquiry and to the best of my knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

 

 

 

Date: September 8, 2003

     

/s/    DEBORAH S. ORLOVE


Deborah S. Orlove

 

Page 6 of 6 pages